Searching News Database: Merck KGaA
HSMN NewsFeed - 16 Aug 2022
Akorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg
Akorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg
HSMN NewsFeed - 6 Jul 2022
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 5 May 2022
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
HSMN NewsFeed - 28 Sep 2021
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
HSMN NewsFeed - 19 Jul 2021
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 9 Jun 2020
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
HSMN NewsFeed - 20 Dec 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
HSMN NewsFeed - 31 Aug 2018
Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America
Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America
HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
HSMN NewsFeed - 25 Apr 2018
Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience
Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience
HSMN NewsFeed - 6 Mar 2018
Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs
Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 1 Dec 2017
EMD Serono Appoints Zhen Su, M.D., MBA to Chief Medical Officer, North America
EMD Serono Appoints Zhen Su, M.D., MBA to Chief Medical Officer, North America
HSMN NewsFeed - 23 Oct 2017
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 13 Jan 2017
Merck KGaA, Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration Partnership
Merck KGaA, Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration Partnership
HSMN NewsFeed - 6 Jan 2017
Viking Therapeutics Announces Senior Level Appointments to Management Team
Viking Therapeutics Announces Senior Level Appointments to Management Team
HSMN NewsFeed - 15 Aug 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
HSMN NewsFeed - 2 Jun 2016
Juniper Pharmaceuticals Announces Planned Retirement of CEO Frank Condella
Juniper Pharmaceuticals Announces Planned Retirement of CEO Frank Condella
HSMN NewsFeed - 24 Mar 2016
Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors
Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors
HSMN NewsFeed - 18 Dec 2015
ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
HSMN NewsFeed - 27 Apr 2015
Synta Announces Chen Schor Named President, Chief Executive Officer and Director
Synta Announces Chen Schor Named President, Chief Executive Officer and Director
HSMN NewsFeed - 27 Mar 2014
Merck Announces Initiation of Phase III Fertility Study with Pergoveris in Poor Ovarian Response Patients
Merck Announces Initiation of Phase III Fertility Study with Pergoveris in Poor Ovarian Response Patients
HSMN NewsFeed - 31 Jan 2014
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
HSMN NewsFeed - 9 Jan 2014
OvaScience Appoints David Stern to Executive Vice President, Global Commercial Operations
OvaScience Appoints David Stern to Executive Vice President, Global Commercial Operations
HSMN NewsFeed - 8 Nov 2013
EMD Serono Announces Appointment of Paris Panayiotopoulos as President and Managing Director
EMD Serono Announces Appointment of Paris Panayiotopoulos as President and Managing Director
HSMN NewsFeed - 3 Sep 2013
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
HSMN NewsFeed - 29 Oct 2012
Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
HSMN NewsFeed - 25 Apr 2012
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
HSMN NewsFeed - 17 Feb 2012
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer
HSMN NewsFeed - 15 Feb 2012
Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
HSMN NewsFeed - 22 Sep 2011
Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer
Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer
HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
HSMN NewsFeed - 23 Sep 2010
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
HSMN NewsFeed - 23 Mar 2010
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
HSMN NewsFeed - 1 Mar 2010
Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO
Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO
HSMN NewsFeed - 2 Feb 2010
Sensors for Medicine and Science, Inc. Names Dr. Paul Strumph as Chief Medical Officer
Sensors for Medicine and Science, Inc. Names Dr. Paul Strumph as Chief Medical Officer
HSMN NewsFeed - 26 Jan 2010
Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss, Ph.D., to Its Board of Directors
Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss, Ph.D., to Its Board of Directors
HSMN NewsFeed - 10 Dec 2009
Vertex Pharmaceuticals Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer
Vertex Pharmaceuticals Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 2 Mar 2009
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
HSMN NewsFeed - 31 Jul 2008
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
HSMN NewsFeed - 10 Jun 2008
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
HSMN NewsFeed - 2 Jun 2008
Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
HSMN NewsFeed - 16 Apr 2008
Merck Announces Planned Investment of $50 Million in Research Center in the US
Merck Announces Planned Investment of $50 Million in Research Center in the US
HSMN NewsFeed - 13 Mar 2008
Clinical Data, Inc. Initiates Second Pivotal Phase III Study of Vilazodone
Clinical Data, Inc. Initiates Second Pivotal Phase III Study of Vilazodone
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 22 Jan 2008
Steve Glass Appointed Vice President and General Manager, BioMarin Europe, Ltd.
Steve Glass Appointed Vice President and General Manager, BioMarin Europe, Ltd.
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
HSMN NewsFeed - 8 Oct 2007
NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer
NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer
HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
HSMN NewsFeed - 3 Sep 2007
Nitec Pharma AG Announces Appointments of CEO & CFO in Preparation for Launch of Lodotra(R)
Nitec Pharma AG Announces Appointments of CEO & CFO in Preparation for Launch of Lodotra(R)
HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
HSMN NewsFeed - 8 Aug 2007
BioCryst Appoints Elliott T. Berger, Ph.D., Senior Vice President of Regulatory Affairs
BioCryst Appoints Elliott T. Berger, Ph.D., Senior Vice President of Regulatory Affairs
HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
HSMN NewsFeed - 9 May 2007
Poniard Pharmaceuticals Appoints Ronald A. Martell President and Chief Operating Officer
Poniard Pharmaceuticals Appoints Ronald A. Martell President and Chief Operating Officer
HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
HSMN NewsFeed - 19 Apr 2007
Merck KGaA and WHO Conclude Partnership to Control Schistosomiasis in Africa
Merck KGaA and WHO Conclude Partnership to Control Schistosomiasis in Africa
HSMN NewsFeed - 14 Mar 2007
Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products
Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products
HSMN NewsFeed - 26 Feb 2007
First patient enrolled in Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer
First patient enrolled in Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer
HSMN NewsFeed - 30 Jan 2007
Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device
Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device
HSMN NewsFeed - 17 Jan 2007
Archemix and Merck KGaA to Collaborate on Aptamer-Based Cancer Therapeutics
Archemix and Merck KGaA to Collaborate on Aptamer-Based Cancer Therapeutics
HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
HSMN NewsFeed - 16 Oct 2006
Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide
Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide
HSMN NewsFeed - 27 Sep 2006
Cenix BioScience and Merck KGaA Sign Framework Agreement for RNAi-Based Drug Discovery
Cenix BioScience and Merck KGaA Sign Framework Agreement for RNAi-Based Drug Discovery
HSMN NewsFeed - 11 Sep 2006
Statement from Dey, L.P. Regarding Pricing Litigation by the U.S. Department of Justice
Statement from Dey, L.P. Regarding Pricing Litigation by the U.S. Department of Justice
HSMN NewsFeed - 15 May 2006
Clinical Data Announces Management Reorganization and Plan to Spin Off Vilazodone Business
Clinical Data Announces Management Reorganization and Plan to Spin Off Vilazodone Business
Additional items found! 122
Members Archive contains
122 additional stories matching:
Merck KGaA
(Password required)
Merck KGaA
(Password required)